New combo therapy aims to make inoperable liver cancer removable

NCT ID NCT07075120

Recruiting now Disease control Sponsor: University of Hawaii Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) and focused radiation before surgery in 15 people with advanced liver cancer that is borderline removable. The goal is to see if this approach is safe and can shrink tumors enough to allow complete surgical removal. The study focuses on Native Hawaiian and Pacific Islander patients, who are often underrepresented in research and have higher death rates from this cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipilimumab and Nivolumab (immunotherapy drugs) plus stereotactic body radiotherapy (focused radiation)
What this could lead to: If successful, this approach could make surgery possible for more patients with advanced liver cancer and improve survival, especially for underserved populations.
What could go wrong: This is a very early, small pilot study with only 15 participants. The combination of treatments may cause serious side effects, and it is unknown if it will work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

The Queen's Medical Center
RECRUITING

Honolulu, Hawaii, 96813, United States
University of Hawai'i Cancer Center
NOT_YET_RECRUITING

Honolulu, Hawaii, 96813, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.